Trilaciclib

SKU: orb1708328

Description

Trilaciclib is an orally bioavailable, short-acting CDK4/6 inhibitor (IC₅₀ 1-4 nM) that induces reversible G1 arrest. It is researched for mitigating chemotherapy-induced myelosuppression and enhancing antitumor immunity in various cancers, with applications in both in vitro cell cycle studies and in vivo preclinical models.

Research Area

Cell Biology

Key Properties

• CAS Number: 1374743-00-6
• MW: 446.55
• Purity: 99.62% (May vary between batches)
• Formula: C₂₄H₃₀N₈O
• SMILES: CN1CCN(CC1)c1ccc(Nc2ncc3cc4C(=O)NCC5(CCCCC5)n4c3n2)nc1
• Target: CDK,Cell Cycle Arrest
• Solubility: DMSO:4.5 mg/mL (10.08 mM)

Bioactivity

• Target IC50:
  CDK4:1 nM|CDK6:4 nM
• In Vivo:
  Method: FVB/N mice were orally administered Trilaciclib (50, 100, 150 mg/kg, single dose), followed by EdU injection to measure the proliferation of bone marrow Lineage-negative cells. Results: Trilaciclib exhibited a dose-dependent effect, effectively suppressing the proliferation of bone marrow HSPCs.
• In Vitro:
  Methods: HS68 cells were treated with Trilaciclib (10-3000nM, 24 hours), fixed and stained with propidium iodide and RNAse A, then analyzed using a Cyan ADP Analyzer. Results: After 24 hours of treatment with 300 nM trilaciclib, the proportion of HS68 cells in the G1 phase reached as high as 98%.

Storage & Handling

• Storage: store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

CDK6, CDK4, Trilaciclib

Compound Identifiers

PubChem CID

68029831